FDA Approves Gadoquatrane, a New Low-Dose MRI Contrast Agent

The FDA has approved gadoquatrane, a new macrocyclic gadolinium-based contrast agent designed for MRI at a lower administered dose than conventional agents. No specific trial numbers reported in source.

• Gadoquatrane is a high-relaxivity macrocyclic gadolinium-based contrast agent (GBCA) intended to achieve diagnostic-quality MRI enhancement at a reduced gadolinium dose compared to standard GBCAs.
• Lower-dose GBCAs are of interest given ongoing safety discussions around gadolinium retention; exact approved indications and clinical trial efficacy/safety numbers not reported in the source snippet.
• Trade-press announcement only — independent peer-reviewed efficacy and safety data should be reviewed before clinical adoption.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.